文献速递妇科肿瘤

奥拉帕利片剂用于铂敏感复发性卵巢癌伴BRCA1/2突变患者的维持治疗(SOLO2/ENGOT-Ov21):一项双盲、随机、安慰剂对照的3期试验

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-07-25

该国际多中心双盲随机安慰剂对照3期试验纳入295例铂敏感复发性高级别浆液性卵巢癌或高级别子宫内膜样癌伴BRCA1/2突变患者,按2:1随机接受奥拉帕利片剂(300 mg每日两次)或安慰剂维持治疗。研究者评估的中位无进展生存期奥拉帕利组为19.1个月,安慰剂组为5.5个月(HR 0.30,95%CI 0.22-0.41,p<0.0001)。奥拉帕利组最常见≥3级不良事件为贫血(19% vs 2%)。

要点

  • 奥拉帕利片剂维持治疗显著延长BRCA1/2突变铂敏感复发性卵巢癌患者的无进展生存期(19.1个月 vs 5.5个月,HR 0.30)。
  • 奥拉帕利组≥3级贫血发生率为19%,显著高于安慰剂组的2%。
  • 奥拉帕利组有1例(1%)患者发生治疗相关不良事件(急性髓系白血病)并导致死亡。

核心结论

  • 奥拉帕利片剂维持治疗为铂敏感复发性卵巢癌伴BRCA1/2突变患者提供了显著的无进展生存期改善,且对生活质量无不利影响。
  • 除贫血外,奥拉帕利相关毒性多为低级别且可控。

研究设计与样本

  • 国际、多中心、双盲、随机、安慰剂对照的3期试验。
  • 纳入295例年龄≥18岁、ECOG体能状态0-1、组织学确诊的复发性高级别浆液性卵巢癌或高级别子宫内膜样癌(包括原发性腹膜或输卵管癌)伴BRCA1/2突变、既往接受过至少二线化疗的铂敏感患者。
  • 患者按2:1随机分配至奥拉帕利片剂(300 mg,两片150 mg片剂,每日两次)或匹配安慰剂组,随机化按既往铂类化疗反应(完全缓解 vs 部分缓解)和无铂间期(6-12个月 vs ≥12个月)分层。
  • 主要终点为研究者评估的无进展生存期,疗效分析基于意向治疗人群,安全性分析纳入至少接受一剂研究治疗的患者。

主要发现

  • 2013年9月3日至2014年11月21日共入组295例患者,随机分配至奥拉帕利组(n=196)或安慰剂组(n=99)。
  • 研究者评估的中位无进展生存期奥拉帕利组为19.1个月(95%CI 16.3-25.7),安慰剂组为5.5个月(95%CI 5.2-5.8),HR 0.30(95%CI 0.22-0.41),p<0.0001。
  • 最常见≥3级不良事件:贫血(奥拉帕利组38例[19%] vs 安慰剂组2例[2%])、疲乏或乏力(8例[4%] vs 2例[2%])、中性粒细胞减少(10例[5%] vs 4例[4%])。
  • 严重不良事件:奥拉帕利组35例(18%) vs 安慰剂组8例(8%);奥拉帕利组最常见为贫血(7例[4%])、腹痛(3例[2%])和肠梗阻(3例[2%]),安慰剂组最常见为便秘(2例[2%])和肠梗阻(2例[2%])。
  • 奥拉帕利组1例(1%)患者发生治疗相关不良事件(急性髓系白血病),结局为死亡。

关键数值与推荐

  • 奥拉帕利片剂剂量为300 mg(两片150 mg片剂),每日两次。
  • 随机化分层因素为既往铂类化疗反应(完全缓解 vs 部分缓解)和无铂间期(6-12个月 vs ≥12个月)。

临床怎么用

  • 对于铂敏感复发性卵巢癌伴BRCA1/2突变且既往接受过至少二线化疗的患者,奥拉帕利片剂300 mg每日两次维持治疗可显著改善无进展生存期。
  • 治疗期间需监测贫血等不良事件,除贫血外毒性多为低级别且可控。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer. We aimed to confirm these findings in patients with a BRCA1 or BRCA2 (BRCA1/2) mutation using a tablet formulation of olaparib. METHODS: This international, multicentre, double-blind, randomised, placebo-controlled, phase 3 trial evaluated olaparib tablet maintenance treatment in platinum-sensitive, relapsed ovarian cancer patients with a BRCA1/2 mutation who had received at least two lines of previous chemotherapy. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance status at baseline of 0-1 and histologically confirmed, relapsed, high-grade serous ovarian cancer or high-grade endometrioid cancer, including primary peritoneal or fallopian tube cancer. Patients were randomly assigned 2:1 to olaparib (300 mg in two 150 mg tablets, twice daily) or matching placebo tablets using an interactive voice and web response system. Randomisation was stratified by response to previous platinum chemotherapy (complete vs partial) and length of platinum-free interval (6-12 months vs ≥12 months) and treatment assignment was masked for patients, those giving the interventions, data collectors, and data analysers. The primary endpoint was investigator-assessed progression-free survival and we report the primary analysis from this ongoing study. The efficacy analyses were done on the intention-to-treat population; safety analyses included patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01874353, and is ongoing and no longer recruiting patients. FINDINGS: Between Sept 3, 2013, and Nov 21, 2014, we enrolled 295 eligible patients who were randomly assigned to receive olaparib (n=196) or placebo (n=99). One patient in the olaparib group was randomised in error and did not receive study treatment. Investigator-assessed median progression-free survival was significantly longer with olaparib (19·1 months [95% CI 16·3-25·7]) than with placebo (5·5 months [5·2-5·8]; hazard ratio [HR] 0·30 [95% CI 0·22-0·41], p<0·0001). The most common adverse events of grade 3 or worse severity were anaemia (38 [19%] of 195 patients in the olaparib group vs two [2%] of 99 patients in the placebo group), fatigue or asthenia (eight [4%] vs two [2%]), and neutropenia (ten [5%] vs four [4%]). Serious adverse events were experienced by 35 (18%) patients in the olaparib group and eight (8%) patients in the placebo group. The most common in the olaparib group were anaemia (seven [4%] patients), abdominal pain (three [2%] patients), and intestinal obstruction (three [2%] patients). The most common in the placebo group were constipation (two [2%] patients) and intestinal obstruction (two [2%] patients). One (1%) patient in the olaparib group had a treatment-related adverse event (acute myeloid leukaemia) with an outcome of death. INTERPRETATION: Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Apart from anaemia, toxicities with olaparib were low grade and manageable. FUNDING: AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017. PMID: 28754483. doi:10.1016/S1470-2045(17)30469-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。